ClinicalTrials.gg
RecruitingNCT03767595Updated Oct 6, 2026

ProACT Post-Approval Study

An interventional study of ProACT Adjustable Continence Therapy for Men in Stress Urinary Incontinence, sponsored by Uromedica. Recruiting at 14 sites in United States. Open to male participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Uromedica · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2019; still recruiting 7 years 9 months later.
Updated Oct 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
145
Allocation
Not applicable
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 190 studies in Urinary Incontinence, Stress with a site in United States — 28 open to participants now, 41 under way, 4 of them phase 3. Urinary Incontinence, Stress · United States.

Planned enrollment
61st of 164
145 · median 99
Started
2019
with 16 others
No phase
109 of 190
18 open now
Primary completion
2031-12
later than 36 of 40 live
Registered
110th of 190
by date

Among the 190 studies in Urinary Incontinence, Stress with a site in United States, this one is the 61st largest by planned enrollment of the 164 interventional ones that give a count, is one of 17 that started in 2019, is one of 109 with no phase, reaches primary completion later than 36 of the 40 other live ones, and was the 110th registered.

Urinary Incontinence, Stress

655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

28 of the 190 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Urinary Incontinence, Stress studies recruiting now, 43 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 50 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Urinary Incontinence, Stress with a site in United States, or all of them as a file.
02

Study summary

The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.

03

Conditions studied

  • Stress Urinary Incontinence
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male of at least 50 years of age.
  2. Subject demonstrates stress urinary incontinence.
  3. Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
  4. Subject is willing and able to undergo surgical implantation of ProACT devices.
  5. Subject is willing and able to comply with study-required

    follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies.

  6. Subject is willing and able to sign the approved .
  7. Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
  8. Subject has a negative urine culture.
  9. Subject has no known urogenital , other than previously treated prostate cancer.
  10. Subject meets ONE of the following criteria:

    1. Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL;
    2. Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
  11. Physician determines subject to be a suitable surgical candidate.

Exclusion criteria

Exclusion Criteria:

  1. Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
  2. Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
  3. Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
  4. Subject has undergone radiation therapy in the prostatic area within the last 12 months.
  5. Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
  6. Subject has an atonic bladder.
  7. Subject had, presently has, or is suspected of having bladder cancer.
  8. Subject has untreated or unsuccessfully treated bladder stones.
  9. Subject has detrusor sphincter dyssynergia.
  10. Subject has known hemophilia or a bleeding disorder.
  11. Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
  12. Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
145 participants (estimated)

Study arms

  • Experimental
    ProACT Adjustable Continence Therapy for Men

    Patients implanted with ProACT Adjustable Continence Therapy for Men

    Device: ProACT Adjustable Continence Therapy for Men

Interventions

  • DeviceProACT Adjustable Continence Therapy for Men

    The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.

06

What researchers measure

Primary outcomes

  1. Urethral Strictures

    Cumulative incidence of ProACT-related clinically relevant urethral strictures over 5 years of follow up.

    Time frame: 5 years

  2. Device Erosions

    Cumulative incidence of ProACT device erosions over 5 years of follow-up.

    Time frame: 5 years

  3. Incontinence Quality of Life Questionnaire (I-QoL)

    Results on Validated Incontinence Quality of Life Questionnaire

    Time frame: 5 years

Other outcomes

  1. Effect of ProACT on Subsequent Stress Urinary Incontinence(SUI) Therapy

    This data will be collected with a "Post ProACT Explant Subsequent Therapy Questionnaire". This questionnaire will ask 3 questions regarding the ProACT therapy 1. Did the ProACT therapy have a detrimental effect on the difficulty of the subsequent implant surgery? 2. Did the ProACT therapy significantly increase the time required to implant the subsequent implant surgery? 3. Did the ProACT therapy increase the surgical complication rate during the subsequent implant surgery? The scale for each question is 0-1. 0 Meaning no effect (a "No" response on the questionnaire) and 1 being some effect ("Yes" response on the questionnaire). No effect (0) on subsequent SUI therapies is the better outcome.

    Time frame: 5 years

07

Study locations

14 of 14 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Dec 2031, 154 months after the start.

Of 41 industry-sponsored interventional studies with no phase under Urinary Incontinence, Stress, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 53. This study's planned 154 months is above that.

Counting every sponsor, half of 268 studies reached it within 19 months; a quarter within 9 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2025 → Dec 2031 and completion Sep 2030 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2018
First posted
Dec 6, 2018
StartActual
Feb 19, 2019
Primary completionEst.
Dec 31, 2031was Sep 2025
CompletionEst.
Dec 31, 2031was Sep 2030
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added
Show 8 added (8 United States)
  • University of Southern California · Los Angeles, United States
  • Sutter Health · Santa Barbara, United States
  • Urological Research Network Corp · Hialeah, United States
  • CHI Health Research · Omaha, United States
  • Lehigh Valley Health Network · Allentown, United States
  • Allegheny Health Network · Pittsburgh, United States
  • Urology Partners of North Texas Research Institute · Arlington, United States
  • DHR Health Institute for Research and Development · McAllen, United States
Oct 6, 2026
Primary completion
Sep 1, 2025→Dec 31, 2031
Oct 6, 2026
Study completion
Sep 1, 2030→Dec 31, 2031
Oct 6, 2026
Contact
Study contact changed: p•••@uromedica-inc.com · •••9880→u•••@coloplast.com · •••8882; r•••@uromedica-inc.com · •••9880→u•••@coloplast.com. See the current contact
Oct 6, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • University of Colorado · Denver, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • University of Florida · Gainesville, United StatesContact person changed (no phone or email listed)
  • Emory University · Atlanta, United StatesContact s•••@emory.edu · •••4729→s•••@emory.eduContact person changed (no phone or email listed)
  • University of Michigan · Ann Arbor, United StatesContact person changed (no phone or email listed)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    8 sites added
    Show 8 added (8 United States)
    • University of Southern California · Los Angeles, United States
    • Sutter Health · Santa Barbara, United States
    • Urological Research Network Corp · Hialeah, United States
    • CHI Health Research · Omaha, United States
    • Lehigh Valley Health Network · Allentown, United States
    • Allegheny Health Network · Pittsburgh, United States
    • Urology Partners of North Texas Research Institute · Arlington, United States
    • DHR Health Institute for Research and Development · McAllen, United States
    Primary completion Sep 1, 2025→Dec 31, 2031
    Study completion Sep 1, 2030→Dec 31, 2031
    Contact Study contact changed: p•••@uromedica-inc.com · •••9880→u•••@coloplast.com · •••8882; r•••@uromedica-inc.com · •••9880→u•••@coloplast.com. See the current contact
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • University of Colorado · Denver, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • University of Florida · Gainesville, United StatesContact person changed (no phone or email listed)
    • Emory University · Atlanta, United StatesContact s•••@emory.edu · •••4729→s•••@emory.eduContact person changed (no phone or email listed)
    • University of Michigan · Ann Arbor, United StatesContact person changed (no phone or email listed)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03767595
Lead sponsor
Uromedica
Responsible party
Sponsor
First posted
Dec 6, 2018
Start date
Feb 19, 2019
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Oct 6, 2026

Study contacts

Matt Kelly, PhD
Contact
usmtk@coloplast.com
6124698882
Lisa DRAPER
Contact
usldr@coloplast.com
Philip Johnson, PhD
study director · Uromedica, Inc. / Coloplast, Corp

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion